ClearPoint Neuro Enters Material Definitive Agreement

TL;DR

ClearPoint Neuro signed a big deal on Feb 28th, filing it today.

AI Summary

ClearPoint Neuro, Inc. announced on March 1, 2024, that it entered into a Material Definitive Agreement on February 28, 2024. The filing also includes financial statements and exhibits related to this agreement. The company was formerly known as MRI Interventions, Inc.

Why It Matters

This filing indicates a significant new contract or partnership for ClearPoint Neuro, which could impact its future revenue and strategic direction.

Risk Assessment

Risk Level: medium — Entering into a material definitive agreement can carry inherent risks related to performance, financial obligations, and market reception.

Key Players & Entities

• ClearPoint Neuro, Inc. (company) — Registrant
• MRI Interventions, Inc. (company) — Former company name
• February 28, 2024 (date) — Date of earliest event reported
• March 1, 2024 (date) — Date of report

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value per share CLPT Nasdaq Capit
• $6.50 — rchase price per share to the public of $6.50 (the "Offering Price"). Pursuant to the
• $14.0 million — from the offering will be approximately $14.0 million (or approximately $16.2 million if the
• $16.2 million — imately $14.0 million (or approximately $16.2 million if the Underwriters exercise their opti

Filing Documents

• tm247180d4_8k.htm (8-K) — 28KB
• tm247180d4_ex1-1.htm (EX-1.1) — 251KB
• tm247180d4_ex5-1.htm (EX-5.1) — 13KB
• tm247180d4_ex5-1img001.jpg (GRAPHIC) — 2KB
• 0001104659-24-029960.txt ( ) — 529KB
• clpt-20240228.xsd (EX-101.SCH) — 3KB
• clpt-20240228_lab.xml (EX-101.LAB) — 33KB
• clpt-20240228_pre.xml (EX-101.PRE) — 22KB
• tm247180d4_8k_htm.xml (XML) — 3KB

01. Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement. On February 28, 2024, ClearPoint Neuro, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Lake Street Capital Markets, LLC, as representative of the several underwriters named in Schedule A thereto (the "Underwriters"), relating to the public offering of 2,307,694 shares of common stock, par value $0.01 per share ("Common Stock"), at a purchase price per share to the public of $6.50 (the "Offering Price"). Pursuant to the Underwriting Agreement, the Company granted the Underwriters a 30-day option to purchase up to an additional 346,154 shares of Common Stock at the Offering Price, less any underwriting discounts and commissions, for use solely in covering any over-allotments. Net proceeds from the offering will be approximately $14.0 million (or approximately $16.2 million if the Underwriters exercise their option to purchase additional shares of Common Stock in full) after deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for general corporate purposes, which may include research and development expenditures, potential acquisitions of or investments in businesses, products and technologies that complement the Company's business, or repayment of indebtedness . The Common Stock was offered and sold pursuant to a preliminary prospectus supplement, dated February 28, 2024, a final prospectus supplement, dated February 28, 2024, and a base prospectus, dated November 20, 2023, relating to the Company's effective shelf registration statement on Form S-3 (File No. 333-275476). The Company expects the offering to close on or about March 4, 2024. The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters,

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Underwriting Agreement, dated as of February 28, 2024, by and between ClearPoint Neuro, Inc. and Lake Street Capital Markets, LLC, as representative of the several underwriters named in Schedule A thereto. 5.1 Opinion of Bass, Berry & Sims PLC regarding the legality of shares. 23.1 Consent of Bass, Berry & Sims PLC (included in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 1, 2024 CLEARPOINT NEURO, INC. By: /s/ Danilo D'Alessandro Danilo D'Alessandro Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR